Implications of serum calcitonin gene-related peptide and type I interferon in systemic lupus erythematosus-associated headaches
- 3 April 2025
- journal article
- Published by SAGE Publications in Lupus
- Vol. 34 (6) , 608-616
Abstract
Objective: Headache is a common neurological symptom in patients with systemic lupus erythematosus (SLE). Calcitonin gene-related peptide (CGRP) is a potential chemical mediator of headaches, while type I interferon (IFN) plays a pivotal role in the immune system of SLE. This study investigated the implications of CGRP and type I IFNs as headache biomarkers in patients with SLE. Methods: We used clinical information and serum samples from 144 patients with SLE from a Japanese multicenter cohort and a biobank. Serum CGRP, IFN-α, and IFN-β levels, which were measured using enzyme-linked immunoassay, were compared among patients with headache, those without headache, and 20 healthy controls (HC). These levels were compared based on the severity of daily disability caused by headaches as determined using the Migraine Disability Assessment. Results: Of the 144 patients, 60 had headache (median age, 42 years; 56 women) and were significantly younger than patients without headache (median age, 49 years; 77 women) ( p < .005). Both groups had a median SLE Disease Activity Index 2000 score of 4.0, which was not significantly different, whereas photosensitivity was significantly more prevalent in patients with headache than in those without headache ( p < .05). Serum CGRP and IFN-α levels were not significantly different between patients with headache, those without headache, and HC. Serum IFN-β levels were significantly higher in patients with headache than in those without headache ( p < .005), while being significantly lower in both patients with and without headache than in HC ( p < .005). No significant differences in serum CGRP, IFN-α and IFN-β levels were observed based on the severity of daily disability related to headaches. Conclusion: Serum CGRP and type I IFNs levels may not be involved in SLE-associated headaches.Keywords
Funding Information
- Shinshu Public Utility Foundation for the Promotion of Medical Science
This publication has 40 references indexed in Scilit:
- Neuropsychiatric involvement in systemic lupus erythematosus: A reviewAutoimmunity Reviews, 2021
- Monitoring Disease Activity in Systemic Lupus Erythematosus With Single‐Molecule Array Digital Enzyme‐Linked Immunosorbent Assay Quantification of Serum Interferon‐αArthritis & Rheumatology, 2018
- Editorial: Splitting Headache (Off)Arthritis & Rheumatism, 2013
- Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort StudyArthritis & Rheumatism, 2013
- Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal periodThe Journal of Headache and Pain, 2009
- The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromesArthritis & Rheumatism, 1999
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990
- Serum interferon levels in patients with systemic lupus erythematosusArthritis & Rheumatism, 1982